Posted by Michael Wonder on 25 Jan 2023
US FDA approves ALK's Odactra (house dust mite allergen extract) tablet for sublingual use as immunotherapy for adolescents
25 January 2023 - Odactra is now indicated to treat house dust mite-induced allergic rhinitis, with or without conjunctivitis, in persons 12 through 17 years of age, in addition to adults 18 through 65 years of age.
ALK announced that the US FDA approved Odactra (house dust mite allergen extract) sublingual tablets for the treatment of house dust mite-induced allergic rhinitis in persons ages 12 through 17.
